KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors

Imatinib and other BCR-ABL1 inhibitors are effective therapies for chronic myeloid leukemia (CML), but these inhibitors target additional kinases including KIT, raising the question of whether off-target effects contribute to clinical efficacy. Based on its involvement in CML pathogenesis, we hypoth...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Corbin, Amie S., O’Hare, Thomas, Gu, Zhimin, Kraft, Ira L., Eiring, Anna M., Khorashad, Jamshid S., Pomicter, Anthony D., Zhang, Tian Y., Eide, Christopher A., Manley, Paul W., Cortes, Jorge E., Druker, Brian J., Deininger, Michael W.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2013
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3894913/
https://ncbi.nlm.nih.gov/pubmed/23887971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-1318
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge